Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics (NASDAQ: MYGN) from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)